Welcome to our dedicated page for Travere Therapeutics news (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.
Travere Therapeutics, Inc. reports developments in rare-disease biopharmaceuticals, with recurring updates on FILSPARI (sparsentan), FDA regulatory actions, commercialization in IgA nephropathy and focal segmental glomerulosclerosis, and financial results. The company focuses on therapies for rare kidney, liver, and metabolic diseases, including sparsentan and the investigational enzyme replacement therapy pegtibatinase.
Company news also covers clinical data presentations, partner-related regulatory and commercial milestones for sparsentan, capital-structure activity, inducement equity grants under Nasdaq rules, and investor-conference participation.
Travere Therapeutics (Nasdaq: TVTX) will participate in several investor conferences, including Canaccord Genuity's 46th Annual Growth Conference on August 11, 2026, the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026, the Citi 2026 Biopharma Back to School Conference on September 9, 2026, and the 2026 Cantor Global Healthcare Conference on September 10, 2026. Live webcasts and 30-day replays will be available on Travere’s investor website.
Travere Therapeutics (Nasdaq: TVTX) reported second quarter 2026 U.S. net product sales of $161.4 million, up from $94.8 million a year ago, driven by FILSPARI U.S. net product sales of $141.1 million, a 96% year-over-year increase, supported by 2,012 new patient start forms from FSGS launch and continued IgAN growth.
GAAP net loss was $34.8 million ($0.37 per share) versus $12.8 million in 2025, impacted by a $40 million inducement expense tied to 2029 convertible note repurchases. Non-GAAP net loss was $9.0 million. Cash, cash equivalents and marketable securities totaled $489.2 million post May 2026 convertible note transactions.
R&D expenses rose to $60.3 million and SG&A to $96.1 million, reflecting pegtibatinase Phase 3 HARMONY progress and FILSPARI commercialization. Travere also in-licensed civorebrutinib from Everest Medicines, paying a $112.5 million upfront in July 2026, and advanced FILSPARI and pegtibatinase clinical programs, with key readouts expected between 2026 and 2027.
Travere Therapeutics (Nasdaq: TVTX) announced it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after the U.S. market close. The company will host a conference call and webcast at 4:30 p.m. ET, with access and a 30-day replay via its investor website.
Travere Therapeutics (Nasdaq: TVTX) reported that on July 10, 2026, its Board Compensation Committee approved Nasdaq Rule 5635(c)(4) inducement equity grants for six new employees, totaling 41,600 shares, split into 18,000 stock options and 23,600 RSUs with four-year vesting schedules.
Travere Therapeutics (Nasdaq: TVTX) announced that chief research officer William Rote, Ph.D. plans to retire in February 2027 after 10 years. Jula Inrig, M.D., current CMO, will become executive vice president, head of research and development and CMO, assuming oversight of the broader R&D organization.
Travere Therapeutics (Nasdaq: TVTX) granted inducement restricted stock units (RSUs) to six new employees on June 10, 2026, covering an aggregate of 32,000 common shares.
The RSUs, granted under Nasdaq Listing Rule 5635(c)(4), vest over four years, with 25% vesting annually, subject to continued service.
Travere Therapeutics (Nasdaq: TVTX) presented long-term open-label extension data from the Phase 3 DUPLEX study of FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS) at the 63rd ERA 2026 Congress.
Patients maintained durable, clinically meaningful proteinuria reductions for up to approximately five years with a safety profile generally consistent with prior findings.
Travere Therapeutics (Nasdaq: TVTX) entered an exclusive licensing and collaboration agreement with Everest Medicines for civorebrutinib, an investigational covalent reversible BTK inhibitor for immune-mediated rare kidney diseases, in all markets outside China and certain East/Southeast Asian countries.
According to Travere, Everest receives a $112.5 million upfront payment, up to about $1.03 billion in milestones across up to five indications, plus tiered royalties. Civorebrutinib has Phase 1/2 proof-of-concept data in primary membranous nephropathy and is planned for evaluation in FSGS, minimal change disease and other indications.
Travere Therapeutics (Nasdaq: TVTX) received a Notice of Allowance from the USPTO for U.S. Patent Application No. 19/253,088 covering certain methods of using FILSPARI (sparsentan) in IgA nephropathy.
Upon issuance, the patent is expected to provide U.S. method-of-use protection into October 2037, and Travere plans to submit it for FDA Orange Book listing.
Travere Therapeutics (Nasdaq: TVTX) granted inducement equity awards on May 10, 2026 to four new employees, covering an aggregate of 48,800 shares of common stock. Grants include 18,000 stock options at $43.51 per share and 30,800 RSUs, issued under Nasdaq Listing Rule 5635(c)(4).